| First Author | Hu A | Year | 2022 |
| Journal | J Immunol | Volume | 208 |
| Issue | 9 | Pages | 2239-2245 |
| PubMed ID | 35418466 | Mgi Jnum | J:325489 |
| Mgi Id | MGI:7281059 | Doi | 10.4049/jimmunol.2100885 |
| Citation | Hu A, et al. (2022) IL-27 Induces CCL5 Production by T Lymphocytes, Which Contributes to Antitumor Activity. J Immunol 208(9):2239-2245 |
| abstractText | IL-27 is a pleiotropic cytokine that exhibits stimulatory/regulatory functions on multiple lineages of immune cells including T lymphocytes. In this study, we demonstrate that IL-27 directly induces CCL5 production by T lymphocytes, particularly CD8(+) T cells in vitro and in vivo. IL-27-induced CCL5 production is IL-27R-dependent. In CD4(+) T cells, IL-27-induced CCL5 production was primarily dependent on Stat1 activation, whereas in CD8(+) T cells, Stat1 deficiency does not abrogate CCL5 induction. A chromatin immunoprecipitation assay revealed that in the CCL5 promoter region, both putative Stat3 binding sites exhibit significant binding to Stat3, whereas only one out of four Stat1 binding sites displays moderate binding to Stat1. In tumor-bearing mice, IL-27 induced dramatic production of CCL5 in tumor-infiltrating T cells. IL-27-induced CCL5 appears to contribute to an IL-27-mediated antitumor effect. This is signified by diminished tumor inhibition in anti-CCL5- and IL-27-treated mice. Additionally, intratumor delivery of CCL5 mRNA using lipid nanoparticles significantly inhibited tumor growth. Thus, IL-27 induces robust CCL5 production by T cells, which contributes to antitumor activity. |
